Lazard Asset Management
AUPH icon

Lazard Asset Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Lazard Asset Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$760K Sell
44,759
-92,596
-67% -$1.48M ﹤0.01% 1301
2026
Q1 		$2.04M Sell
137,355
-106,820
-44% -$1.56M ﹤0.01% 883
2025
Q4 		$3.89M Sell
244,175
-111,494
-31% -$1.58M 0.01% 632
2025
Q3 		$3.93M Sell
355,669
-443,089
-55% -$4.84M 0.01% 645
2025
Q2 		$6.76M Sell
798,758
-446,274
-36% -$3.58M 0.01% 647
2025
Q1 		$10M Buy
1,245,032
+648,643
+109% +$5.25M 0.02% 493
2024
Q4 		$5.36M Buy
596,389
+461,430
+342% +$3.76M 0.01% 628
2024
Q3 		$989K Buy
134,959
+116,093
+615% +$720K ﹤0.01% 1079
2024
Q2 		$107K Buy
+18,866
New +$99.4K ﹤0.01% 1733
2024
Q1 		– Sell
-8,641
Closed -$76K – 2049
2023
Q4 		$76K Sell
8,641
-46,787
-84% -$385K ﹤0.01% 1762
2023
Q3 		$430K Buy
55,428
+32,137
+138% +$314K ﹤0.01% 1185
2023
Q2 		$224K Buy
+23,291
New +$242K ﹤0.01% 1312
2023
Q1 		– Sell
-8,865
Closed -$38K – 2294
2022
Q4 		$38K Sell
8,865
-106
-1% -$615 ﹤0.01% 1921
2022
Q3 		$67K Buy
8,971
+3,671
+69% +$31.8K ﹤0.01% 1660
2022
Q2 		$53K Hold
5,300
– – ﹤0.01% 1784
2022
Q1 		$65K Buy
5,300
+3,298
+165% +$51K ﹤0.01% 1610
2021
Q4 		$45K Buy
+2,002
New +$47.4K ﹤0.01% 1781
2021
Q2 		– Sell
-3,520
Closed -$45K – 1958
2021
Q1 		$45K Buy
+3,520
New +$51.1K ﹤0.01% 1477

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lazard Asset Management's AUPH Position: Q2 2026 in Review

Lazard Asset Management reduced its Aurinia Pharmaceuticals (AUPH) stake by 67% in Q2 2026, selling an estimated $1.48M and leaving 44,759 shares worth $760K. The position accounts for ﹤0.01% of the portfolio, ranked #1301.

Lazard Asset Management first reported a position in AUPH in Q1 2021 and has held it in 18 quarters since. The position peaked at $10M in Q1 2025. 282 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Lazard Asset Management held 44,759 shares of Aurinia Pharmaceuticals worth $760K as of Q2 2026.
  • Lazard Asset Management sold 92,596 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $1.48M.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #1301 holding.
  • Lazard Asset Management first reported a position in Aurinia Pharmaceuticals in Q1 2021 and has held it in 18 quarters since.
  • Lazard Asset Management's Aurinia Pharmaceuticals position peaked at $10M in Q1 2025.
  • 282 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.